Suppr超能文献

万古霉素耐药肠球菌:血液科患者医院定植的危险因素:一项配对病例对照研究。

Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study.

机构信息

Department of Infectious Diseases, Azienda Ospedaliero-Universitaria, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, 41122, Italy.

Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Via del Pozzo 71, Modena, 41122, Italy.

出版信息

Antimicrob Resist Infect Control. 2023 Nov 13;12(1):126. doi: 10.1186/s13756-023-01332-x.

Abstract

BACKGROUND

Vancomycin-resistant enterococcus (VRE) was the fastest growing pathogen in Europe in 2022 (+ 21%) but its clinical relevance is still unclear. We aim to identify risk factors for acquired VRE rectal colonization in hematological patients and evaluate the clinical impact of VRE colonization on subsequent infection, and 30- and 90-day overall mortality rates, compared to a matched control group.

METHODS

A retrospective, single center, case-control matched study (ratio 1:1) was conducted in a hematological department from January 2017 to December 2020. Case patients with nosocomial isolation of VRE from rectal swab screening (≥ 48 h) were matched to controls by age, sex, ethnicity, and hematologic disease. Univariate and multivariate logistic regression compared risk factors for colonization.

RESULTS

A total of 83 cases were matched with 83 controls. Risk factors for VRE colonization were febrile neutropenia, bone marrow transplant, central venous catheter, bedsores, reduced mobility, altered bowel habits, cachexia, previous hospitalization and antibiotic treatments before and during hospitalization. VRE bacteraemia and Clostridioides difficile infection (CDI) occurred more frequently among cases without any impact on 30 and 90-days overall mortality. Vancomycin administration and altered bowel habits were the only independent risk factors for VRE colonization at multivariate analysis (OR: 3.53 and 3.1; respectively).

CONCLUSIONS

Antimicrobial stewardship strategies to reduce inappropriate Gram-positive coverage in hematological patients is urgently required, as independent risk factors for VRE nosocomial colonization identified in this study include any use of vancomycin and altered bowel habits. VRE colonization and infection did not influence 30- and 90-day mortality. There was a strong correlation between CDI and VRE, which deserves further investigation to target new therapeutic approaches.

摘要

背景

万古霉素耐药肠球菌(VRE)是 2022 年欧洲增长最快的病原体(增长 21%),但其临床相关性尚不清楚。我们旨在确定血液科患者获得性 VRE 直肠定植的危险因素,并评估 VRE 定植对随后感染以及与匹配对照组相比的 30 天和 90 天总死亡率的临床影响。

方法

这是一项回顾性、单中心、病例对照匹配研究(比例为 1:1),于 2017 年 1 月至 2020 年 12 月在血液科进行。病例患者为从直肠拭子筛查(≥48 小时)中分离出的医院获得性 VRE,通过年龄、性别、种族和血液疾病与对照组匹配。单变量和多变量逻辑回归比较了定植的危险因素。

结果

共 83 例患者与 83 例对照匹配。VRE 定植的危险因素包括发热性中性粒细胞减少症、骨髓移植、中心静脉导管、褥疮、活动能力下降、肠道习惯改变、恶病质、既往住院和住院期间的抗生素治疗。VRE 菌血症和艰难梭菌感染(CDI)在无任何影响的情况下在病例中更频繁发生30 天和 90 天的总死亡率。万古霉素治疗和肠道习惯改变是多变量分析中 VRE 定植的唯一独立危险因素(OR:3.53 和 3.1;分别)。

结论

迫切需要制定抗菌药物管理策略,以减少血液科患者中革兰氏阳性菌覆盖的不当使用,因为本研究确定的 VRE 医院定植的独立危险因素包括万古霉素的任何使用和肠道习惯改变。VRE 定植和感染并未影响 30 天和 90 天的死亡率。CDI 和 VRE 之间存在很强的相关性,值得进一步研究以确定新的治疗方法。

相似文献

1
Vancomycin resistant enterococcus risk factors for hospital colonization in hematological patients: a matched case-control study.
Antimicrob Resist Infect Control. 2023 Nov 13;12(1):126. doi: 10.1186/s13756-023-01332-x.
3
The local hospital milieu and healthcare-associated vancomycin-resistant enterococcus acquisition.
J Hosp Infect. 2019 Jan;101(1):69-75. doi: 10.1016/j.jhin.2018.07.018. Epub 2018 Jul 17.
4
Gut Microbiota Predict Expansion but Not Vancomycin-Resistant Acquisition.
mSphere. 2020 Nov 18;5(6):e00537-20. doi: 10.1128/mSphere.00537-20.
5
Risk Factors and Outcomes of Vancomycin-Resistant Colonization in Patients on Peritoneal Dialysis: A Single-Center Study in Hong Kong.
Perit Dial Int. 2017 Sep-Oct;37(5):556-561. doi: 10.3747/pdi.2016.00278. Epub 2017 Mar 27.

引用本文的文献

3
Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML-One Step Closer to Personalized Medicine.
Biomedicines. 2025 Jul 18;13(7):1761. doi: 10.3390/biomedicines13071761.
5
Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
JAMA Netw Open. 2025 Jul 1;8(7):e2517834. doi: 10.1001/jamanetworkopen.2025.17834.
7
Experience in Implementing Colonization Screening in a Multidisciplinary County Clinical Hospital in Romania.
Microorganisms. 2025 Mar 28;13(4):775. doi: 10.3390/microorganisms13040775.
8
AI modeling for outbreak prediction: A graph-neural-network approach for identifying vancomycin-resistant enterococcus carriers.
PLOS Digit Health. 2025 Apr 10;4(4):e0000821. doi: 10.1371/journal.pdig.0000821. eCollection 2025 Apr.

本文引用的文献

1
Microbiota and Hematological Diseases.
Int J Hematol Oncol Stem Cell Res. 2022 Jul 1;16(3):164-173. doi: 10.18502/ijhoscr.v16i3.10139.
2
Enterococci enhance Clostridioides difficile pathogenesis.
Nature. 2022 Nov;611(7937):780-786. doi: 10.1038/s41586-022-05438-x. Epub 2022 Nov 16.
3
Prevention of device-related infections in patients with cancer: Current practice and future horizons.
CA Cancer J Clin. 2023 Mar;73(2):147-163. doi: 10.3322/caac.21756. Epub 2022 Sep 23.
4
SER-109, an Oral Microbiome Therapy for Recurrent Infection.
N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516.
6
Molecular determination of genes among clinical isolates of enterococci at a hospital setting.
Saudi J Biol Sci. 2021 May;28(5):2895-2899. doi: 10.1016/j.sjbs.2021.02.022. Epub 2021 Feb 17.
9
Gut Microbial Dysbiosis in the Pathogenesis of Gastrointestinal Dysmotility and Metabolic Disorders.
J Neurogastroenterol Motil. 2021 Jan 30;27(1):19-34. doi: 10.5056/jnm20149.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验